Grifols Sa Barc Ord New (GIFLF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and thank you for joining us today for Grifols second quarter 2026 earnings call. My name is Daniel Segarra and I serve as a head of investor relations and sustainability. Today I'm joined by Grifols chief executive officer Nat Shabia, president of Biopharma Roland Vandeler and chief financial officer Rahul Srinivasan. As this is Transcription by CastingWords Turning to slide two, I would like to remind everyone that forward-looking statements may be made during this call. This may include, among other things, comments regarding the company's future operating and financial performance, statements about our future expectation, clinical developments, regulatory timelines, and the potential success of our product candidates. These statements are based on current expectation and available information as of the date of this call and are subject to certain risks and uncertainties that may cause actual results to differ materially from those discussed today. Grateful financial statements are prepared in accordance with EU, IFRS and other applicable reporting provisions including alternative performance measures or APMs as defined by the European Securities and Markets Authority. Grifols Management uses APMs to evaluate financial performance as the basis for operational and strategic decision making. These APMs are prepared for all the time periods presented in this document. As announced, the Board of Directors has decided to initiate a process to evaluate a potential IPO of the Grifols U.S. biopharma business. Any such transaction remains subject to legal and regulatory requirements. Thank you Danny and thank you all for joining us today. The second quarter played out in line with our expectations, allowing us to deliver a solid first half of the year and ke...